前收市價 | 0.1000 |
開市 | 0.0300 |
買盤 | 0.0400 |
賣出價 | 0.2000 |
拍板 | 140.00 |
到期日 | 2025-01-17 |
今日波幅 | 0.0300 - 0.1000 |
合同範圍 | 無 |
成交量 | |
未平倉合約 | 4.22千 |
EXEL is set to evaluate investigational zanzalintinib in combination with Merck;s Keytruda (pembrolizumab) and Welireg in head and neck cancer and renal cell carcinoma, respectively.
We recently published a list of 7 Most Profitable Cheap Stocks To Invest In. In this article, we are going to take a look at where Merck & Co. (NYSE:MRK) stands against the other most profitable cheap stocks to invest in. Insights on Small Caps, Tech, and More Sherry Paul, Morgan Stanley Private Wealth Management […]
We recently compiled a list of the 10 Most Undervalued Quality Stocks To Buy According To Analysts. In this article, we will look at where Merck & Co. Inc. (NYSE:MRK) ranks among the most undervalued quality stocks to buy according to analysts. Are More Rate Cuts Necessary to Maintain The Current Economic Trajectory? Despite global […]